sourcing the best research evidence in ophthalmology
November 1, 2014
Clinical trial
Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R.
Am J Ophthalmol. 2014 Nov;158(5):1032-8. Full text | Metrics.
Main finding: Aflibercept is an effective treatment for macular edema after CRVO
Participants: ≥18 yo with centre-involving macular oedema secondary to BRVO, BCVA 20/40-20/320, mean central subfield thickness ≥250 μm
Intervention:
Group 1: Intravitreal Aflibercept 2mg q4weekly (first 20 weeks, then AFLI PRN) Group 2: Sham (first 48 weeks, then AFLI PRN)
Share This Article :
Source Archive